Conventional CAR T cell therapies have revolutionized the treatment of B-cell malignancies by genetically engineering a patient’s own T cells to recognize and destroy cancer cells expressing the CD19 antigen. However, despite remarkable initial successes, several critical challenges emerge. One of the foremost issues is antigen escape, wherein tumor cells downregulate or lose the targeted antigen, thereby evading immune recognition. This results in relapse and limits long-term efficacy. Another formidable challenge is the use of allogeneic, or donor-derived, CAR T cells that, while offering advantages such as immediate availability and uniform quality, provoke alloimmune responses that can lead to graft-versus-host disease and rapid CAR T cell clearance.

The innovation reported by Zhang, Li, O’Dair, and colleagues combines these two elements in an elegant and highly functional design. By arming CD19-targeting CAR T cells with an additional chimeric antigen receptor directed against CD70, a molecule implicated in alloimmune rejection, the researchers have orchestrated a dual-function therapeutic agent capable of both sustainable tumor targeting and evasion of host immune rejection. CD70 expression is upregulated on activated immune cells during alloimmune reactions, making it an ideal target to suppress these unwanted immune responses without broadly compromising immune function.

Technically, the study employed sophisticated gene engineering techniques to generate bispecific CAR T cells, which simultaneously express CARs against CD19 and CD70. The anti-CD70 CAR functions as a built-in immune checkpoint inhibitor, tempering the immune activation that prompts rejection of allogeneic T cells. This dual targeting paradigm enables the CAR T cells to persist longer in the host bloodstream, exert sustained cytotoxicity against malignant B cells, and crucially, reduce the incidence of graft-versus-host complications. The researchers validated these effects in rigorous in vitro assays and robust in vivo models that recapitulate the tumor microenvironment and alloimmune interactions.

A pivotal mechanistic insight from the study reveals that the presence of the anti-CD70 CAR diminishes host T cell and natural killer (NK) cell-mediated destruction of the infused allogeneic CAR T cells. By selectively erasing the lymphocyte populations responsible for rejection, the engineered therapies effectively cloak themselves, maintaining their cytolytic activity against tumor cells. This finding not only exemplifies the power of precise immunomodulation but also extends the therapeutic window, allowing repeated dosing regimens that were previously untenable with allogeneic strategies.

The implications of overcoming antigen escape are equally transformative. Tumor heterogeneity and plasticity have long imperiled the durability of CAR T cell therapies, as cancer cells continuously evolve to circumvent immune targeting. The augmented allogeneic CAR T cells demonstrate an enhanced ability to recognize variant or residual populations of B cells by relying on dual antigen recognition. Should CD19 expression diminish, the therapy’s anti-CD70 arm helps maintain selective pressure against the tumor environment’s supportive immune components, disrupting the mechanisms that favor tumor persistence and relapse.

Clinically, this dual targeting approach has the potential to expand off-the-shelf CAR T cell therapies dramatically. Current autologous CAR T protocols involve complex, time-intensive manufacturing and relinquish treatment opportunities to patients with aggressive disease progression. Ready-to-use allogeneic CAR T cell products, equipped with anti-CD70 CARs to circumvent rejection, could democratize access to lifesaving immunotherapies globally. Moreover, the decreased risk of graft-versus-host disease will alleviate the burden of severe toxicities, improving patient safety profiles and quality of life during treatment.

Beyond hematological malignancies, the principles elucidated in this study open avenues for targeting solid tumors, where antigen heterogeneity and immune modulation represent formidable barriers. The ability to engineer multi-specific CAR T cells that simultaneously eliminate tumor cells and modulate the host immune response may be applicable to an array of cancers and chronic infections. This paradigm underscores a shift toward intelligent, adaptable cell therapies that orchestrate complex immune dynamics rather than relying on singular antigen targeting.

The research team also highlighted the scalability and manufacturability of their bispecific CAR T cells, utilizing lentiviral vectors and optimized culture conditions to preserve cell viability and functional potency. This addresses critical translational hurdles, ensuring that promising preclinical findings can be efficiently leveraged for rapid clinical development. As a result, several clinical trials investigating similar constructs are anticipated within the next few years, potentially accelerating the approval timeline for next-generation CAR T products.

Safety remains paramount in CAR T cell therapies, particularly with the introduction of new antigen targets and combined modalities. The anti-CD70 CAR design incorporates safety switches to facilitate the selective depletion of infused T cells in the event of unanticipated toxicities, reflecting a robust risk mitigation strategy. Continued monitoring of cytokine release syndrome and neurotoxicity in preclinical models has shown favorable profiles, but the authors caution that comprehensive clinical evaluation will be necessary to confirm these results.

This work also underscores the importance of integrating immunological insights with bioengineering advances. The strategic targeting of CD70—an immune checkpoint molecule beyond classical PD1/CTLA4 axes—demonstrates how deeper understanding of immune cell interactions can inform novel therapeutic strategies. Such innovations will likely become increasingly common as the field embraces complexity rather than shying away from it.

In conclusion, the study by Zhang and colleagues represents a monumental step forward in the evolution of CAR T cell therapy. By ingeniously combining allogeneic CD19 CAR T cells with an anti-rejection CD70 CAR, the team has addressed the twin issues of antigen escape and alloimmune rejection that have long constrained therapeutic efficacy. This breakthrough paves the way for safer, more effective, and more accessible immunotherapies that could transform cancer treatment paradigms worldwide.

As the scientific community eagerly awaits clinical trial data, this pioneering approach exemplifies the power of precision immunotherapy design to overcome biological challenges. It stands as a beacon for future research striving to harness the full potential of engineered immune cells against cancer and other diseases, setting a new standard for innovation and hope in medicine.

Subject of Research: Development of allogeneic CD19 CAR T cells enhanced with an anti-rejection CD70 CAR to prevent antigen escape and evade host alloimmune responses in cancer immunotherapy.

Article Title: Allogeneic CD19 CAR T cells armed with an anti-rejection CD70 CAR overcome antigen escape and evade alloimmune responses.

Article References:
Zhang, K., Li, Z., O’Dair, M.K. et al. Allogeneic CD19 CAR T cells armed with an anti-rejection CD70 CAR overcome antigen escape and evade alloimmune responses. Nat Commun (2026). https://doi.org/10.1038/s41467-026-71904-z

Image Credits: AI Generated

The tumor microenvironment (TME) represents a formidable obstacle for immune-based therapies, as it enables tumor cells to evade immune surveillance through multiple pathways, including the secretion of immunosuppressive molecules like VEGF. VEGF plays a multifaceted role by stimulating aberrant blood vessel formation, facilitating tumor survival in hypoxic conditions, and creating a physical and chemical fortress that restricts immune cell infiltration and function. Traditional therapeutic strategies that systemically inhibit VEGF, such as the monoclonal antibody bevacizumab, suffer from limited efficacy and systemic toxicities, which have constrained their clinical success.

The UCLA research team has circumvented these limitations by genetically engineering CAR-T cells to secrete a specialized single-chain variable fragment (scFv) antibody that neutralizes VEGF locally within the tumor microenvironment. This fusion of direct tumor killing and simultaneous VEGF blockade heralds a transformative advancement in CAR-T technology, effectively “arming” the T cells with dual functionality. By producing VEGF blockers at the tumor site, these armored CAR-T cells circumvent the need for systemic drug administration, potentially minimizing the off-target effects and maximizing therapeutic potency exactly where it is most required.

Preclinical testing conducted in rigorous mouse models of glioblastoma and ovarian cancer demonstrated striking therapeutic benefits of the armored CAR-T cells compared to conventional CAR-T therapy and systemic VEGF inhibition. In ovarian cancer models, the engineered cells not only decelerated tumor progression but enhanced survival rates and boosted the production of interferon-gamma, a cytokine critical for triggering robust immune responses against malignancy. The efficacy was further exemplified in highly aggressive glioma mouse models, where the armored CAR-T completely eradicated tumors in a majority of subjects, whereas traditional CAR-T cells achieved significantly lower complete response rates.

Intriguingly, the study revealed that standard CAR-T therapy paradoxically exacerbated adverse tumor features by promoting abnormal neovascularization and increasing tumor hypoxia, which could undermine immune cell function. The armored CAR-T cells, conversely, normalized the tumor vasculature, alleviating oxygen deprivation and creating a more favorable terrain for immune-mediated tumor eradication. This normalization effect likely contributes considerably to the observed enhanced functionality and energetic state of the engineered CAR-T cells, as well as to the recruitment and activation of endogenous immune populations.

The therapeutic innovation centers on the concept that the immunosuppressive tumor microenvironment is modifiable and can be “re-educated” rather than only targeted for destruction. By locally delivering VEGF inhibition through CAR-T cells themselves, the therapy realigns the tumor milieu from hostile to permissive, enabling both the engineered and native immune cells to perform their anti-cancer functions more effectively. This dual modality not only intensifies the CAR-T cell cytotoxicity but also promotes a systemic anti-tumor immune response, offering a potentially durable and comprehensive therapeutic benefit.

While VEGF blockade is not new to cancer treatment, this approach using CAR-T cells as living drug factories represents a paradigm shift, leveraging genetic engineering to overcome the chronic challenges faced by conventional immunotherapies in solid tumors. This strategy also avoids the logistical and pharmacokinetic hurdles of repeated systemic drug administration, instead harnessing the CAR-T cells’ ability to proliferate and sustain VEGF inhibition dynamically in situ, adapting to tumor growth and heterogeneity.

The implications of this research are vast, given the historical difficulty in treating malignancies like glioblastoma and ovarian cancer—tumor types notorious for their aggressiveness, recurrence, and resistance to standard therapies. The armored CAR-T cells’ capacity to induce complete remission in preclinical glioma models underscores the potential to redefine therapeutic outcomes for patients facing these deadly cancers, which currently have very limited effective treatment options.

Led by Yvonne Chen, PhD, co-director of the Tumor Immunology and Immunotherapy Program at UCLA’s Jonsson Comprehensive Cancer Center, this study sets the stage for next-generation immunotherapy designs that integrate tumor microenvironment modification with targeted immunoassault. Chen emphasizes that by reshaping the hostile microenvironment, this approach does not merely attack tumor cells but also enlists the body’s own immune system to join the battle, which may lead to sustained long-term remission.

The partnership with Dr. Han-Chung Wu’s team at Academia Sinica in Taiwan facilitated the creation of the novel VEGF-targeting scFv, a crucial element allowing the CAR-T cells to maintain focused VEGF blockade. This international collaboration exemplifies the increasingly interdisciplinary nature of modern biomedical innovation, combining advances in molecular engineering, immunology, and cancer biology.

Ongoing refinements and future clinical development will determine how this technology translates to the human oncology landscape, but the preclinical data provide a robust proof-of-concept that armored CAR-T cells could redefine therapy for solid tumors. Their ability to counteract VEGF-mediated suppression and hypoxia-induced resistance mechanisms marks a meaningful advance in overcoming the entrenched immunotherapy barriers posed by solid malignancies.

This pioneering research heralds a new frontier in cancer immunotherapy where multifunctional, self-sustaining CAR-T cells can penetrate and dismantle the protective tumor microenvironment whilst orchestrating an amplified anti-cancer immune response throughout the body. If successful in clinical trials, this approach could significantly broaden the applicability and effectiveness of CAR-T therapies beyond hematologic cancers and open new avenues for treating some of the most lethal solid tumors faced by patients worldwide.

Subject of Research: Next-generation CAR-T cell therapy targeting VEGF to neutralize the tumor microenvironment in solid cancers

Article Title: Not provided

News Publication Date: Not provided

Web References: Not provided

References: Not provided

Image Credits: Not provided

Keywords: CAR-T therapy, tumor microenvironment, VEGF blockade, immune suppression, solid tumors, glioblastoma, ovarian cancer, immunotherapy, single-chain variable fragment (scFv), tumor vasculature, hypoxia, oncology

Ovarian cancer remains one of the most formidable adversaries in oncology, largely due to its late-stage diagnosis and the intricacies involved in its treatment. Conventional therapies like chemotherapy and radiation, while effective to some extent, often fail to provide the sustained response necessary for long-term remission. TCR therapy presents a novel alternative by allowing for a more personalized treatment approach. It involves the genetic engineering of T cells to express specific receptors that can identify and bind to tumor-associated antigens present on the surface of ovarian cancer cells.

The essence of T-cell receptor therapy lies in its specificity. Unlike traditional treatments that indiscriminately target both cancerous and healthy cells, TCR therapy is designed to precisely hone in on cancer cells. This specificity not only enhances the effectiveness of the treatment but also significantly reduces the collateral damage to normal cells, which is often the hallmark of conventional cancer treatments. This is particularly crucial in ovarian cancer, where preserving the quality of life during treatment is paramount.

Central to the advancement of TCR therapy is the identification of suitable tumor antigens. Wang and colleagues have highlighted the significance of tumor-associated antigens, which are proteins or molecules expressed abnormally in cancer cells compared to normal cells. The successful identification and characterization of these antigens is essential for developing effective TCR therapies. Once these antigens are pinpointed, T cells can be engineered to express receptors that specifically recognize and attack ovarian cancer cells.

Despite the promising outlook of TCR therapy, several challenges persist that must be addressed for its widespread implementation in clinical settings. One major hurdle is the tumor microenvironment. Ovarian tumors often create an immunosuppressive environment that can inhibit the function of infused T cells. This poses a significant challenge as it may diminish the efficacy of TCR therapies, leading to inadequate responses in patients. Understanding and manipulating the tumor microenvironment may thus provide vital insights into enhancing the effectiveness of T-cell therapy.

Another critical challenge lies in the variability of patient responses to TCR therapy. Not all patients exhibit the same immune response to treatment, which can be attributed to genetic differences and variations in tumor biology. This heterogeneity necessitates a more personalized approach in selecting candidates for TCR therapy, as well as tailoring the treatment to better suit individual patient profiles. Ongoing research is focused on elucidating the factors that contribute to these differences, which will be pivotal for optimizing therapeutic efficacy.

Moreover, the technical aspects of TCR therapy, such as the method of T-cell extraction and genetic modification, pose additional complexities. The process involves isolating T cells from a patient’s blood, engineering them to express the desired TCRs, and then infusing these modified T cells back into the patient. Each step must be meticulously executed to ensure the highest quality and viability of T cells, which can be labor-intensive and costly.

As with many emerging therapies, safety remains a paramount concern in the application of TCR therapy. The potential for adverse effects, such as cytokine release syndrome or off-target effects where T cells attack healthy cells, must be carefully monitored. Researchers are actively working on developing strategies to mitigate these risks, ensuring that the benefits of TCR therapy outweigh the potential drawbacks.

The future of TCR therapy in ovarian cancer looks promising, particularly with the advancements in genomic technologies and our understanding of cancer biology. The ability to sequence genomes and identify tumor mutations has revolutionized the stage for personalized medicine. As researchers like Wang et al. continue to pave the way for TCR therapy, they contribute significant knowledge that could potentially reshape the treatment landscape for ovarian cancer patients.

Collaboration among scientists, clinicians, and regulatory bodies will be crucial in overcoming the hurdles that TCR therapy faces. Multi-disciplinary approaches combining immunology, molecular biology, and clinical expertise will be essential in refining techniques and broadening patient access. This collective effort will hopefully lead to breakthroughs that not only improve response rates but also extend survival and enhance the quality of life for patients grappling with ovarian cancer.

Ultimately, the success of TCR therapy will hinge on a comprehensive understanding of both its biological framework and the specific characteristics of the tumors it aims to treat. Continuous research and innovation will be vital in unlocking the full potential of this therapy, paving the way for it to become a standard treatment option for ovarian cancer.

In conclusion, T-cell receptor therapy stands at the forefront of cancer immunotherapy, representing a transformative approach in the management of ovarian cancer. With ongoing research efforts to tackle the inherent challenges, the hope remains that this promising therapy will soon provide a viable and effective option for patients who desperately need new avenues of treatment.

Subject of Research: T-cell receptor therapy in ovarian cancer

Article Title: T-cell receptor therapy in ovarian cancer: concepts and challenges

Article References: Wang, X., Li, Z., Zhang, M. et al. T-cell receptor therapy in ovarian cancer: concepts and challenges. J Ovarian Res 18, 256 (2025). https://doi.org/10.1186/s13048-025-01831-y

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s13048-025-01831-y

Keywords: T-cell receptor therapy, ovarian cancer, immunotherapy, tumor microenvironment, personalized medicine

CAR T-cell therapy represents a generational leap in the battle against malignancies, offering a personalized approach by harnessing the body’s immune response. Specifically, this therapy involves the genetic engineering of a patient’s T-cells to express a receptor that targets and destroys cancer cells. Despite the growing excitement surrounding its promise, this revolutionary treatment avenue is not without its challenges, particularly concerning efficacy and safety outcomes. Hence, understanding the predictive variables is indispensable for refining therapeutic strategies and mitigating adverse effects.

The authors have conducted an exhaustive examination of existing literature to synthesize insights into factors that may herald better patient outcomes. They reviewed numerous studies that evaluate the performance of CAR T-cell therapies in DLBCL, focusing on identifying the elements that can serve as predictors of success or failure. This analysis sheds light on several clinical characteristics, treatment-related factors, and patient demographics that could influence overall survival, response rates, and potential complications.

Among the various parameters assessed, patient age emerges as a critical factor in determining treatment success. Younger patients typically exhibit better responses compared to their older counterparts. This may be attributed to a more robust immune system capable of mounting a vigorous attack against malignant cells post-CAR T-cell infusion. Coupled with age, baseline tumor burden plays an essential role in predicting outcomes. Patients with lower disease volumes at the outset are likely to benefit more from CAR T-cell therapy, reinforcing the importance of early detection and intervention.

In addition to these intrinsic factors related to the patient’s physical state, the review also delves into treatment variables such as the type of CAR T-cell construct utilized and the specific manufacturing processes. Different constructs can yield varying immune responses; thus, identifying the optimal CAR design could hold the key to maximizing efficacy. Furthermore, the review emphasizes that the manufacturing quality of CAR T-cells—ranging from the transduction efficiency to the final product’s purity—can significantly impact therapeutic outcomes.

Side effects of CAR T-cell therapy, notably cytokine release syndrome (CRS) and neurotoxicity, are pivotal considerations that can compromise patient safety. The review meticulously discusses these adverse effects, underscoring the necessity for monitoring and managing them effectively. It posits that achieving a thorough understanding of which patient demographics are at higher risk of severe toxicity may assist providers in instituting preemptive measures, ensuring that the benefits of this groundbreaking therapy are not eclipsed by its detriments.

Moreover, the review highlights the significance of biomarker discovery in the context of CAR T-cell therapy. Identifying reliable biomarkers that can guide therapeutic decisions and predict individual responses is an area ripe for exploration. Such markers could tailor treatment regimens to patients, enhancing the concept of personalized medicine in oncology. Cases have shown that certain biomarkers correlate with better outcomes, and future research endeavors ought to emphasize this frontier.

As the field continues to evolve, the need for real-world evidence becomes paramount. The review discusses the discrepancy between clinical trial results and actual patient outcomes in broader populations. Real-world studies can help calibrate the findings of controlled trials, providing a nuanced understanding of how CAR T-cell therapies perform under diverse conditions.

The application of advanced analytical techniques, such as machine learning and big data analytics, could further refine predictive models surrounding CAR T-cell immunotherapy. By sifting through vast datasets, researchers can uncover hidden patterns that may otherwise elude traditional statistical approaches. These technological advances are likely to streamline the identification of prognostic factors and enhance treatment protocols, fundamentally transforming patient care in the realm of hematologic malignancies.

In summary, SCHLEIFENBAUM ET AL. provide a comprehensive overview of the current landscape of CAR T-cell therapies in diffuse large B-cell lymphoma. Their systematic literature review serves as both a critical resource for healthcare professionals and a clarion call for continued research in the field. As our understanding of these treatments grows, so too will our ability to address the numerous challenges they present. The inherent complexity of cancer calls for an unrelenting pursuit of knowledge, advocacy for innovation, and a steadfast commitment to patient-centered care.

The urgent need for advancements in therapies for DLBCL cannot be overstated. With the findings presented by Schleifenbaum and colleagues, future initiatives can focus not only on developing more effective CAR T-cell constructs but also on integrating multi-modal strategies that encompass genetic, phenotypic, and environmental factors affecting treatment outcomes. In a landscape often characterized by uncertainty, these insights illuminate a path toward improved prognostic assessment and treatment modalities.

As the body of research grows, ongoing collaboration between scientists, clinicians, and biotechnology firms will be essential. Such partnerships offer the potential to pioneer new methods, streamline existing protocols, and ultimately improve the lives of patients grappling with this complex disease. By continually revisiting and refining our approach to CAR T-cell therapy, we not only honor the groundbreaking work already accomplished but also lay the groundwork for the next generation of cancer treatments.

In conclusion, thorough discourse surrounding CAR T-cell therapies highlights the profound changes happening in the oncology field. As researchers like Schleifenbaum et al. forge ahead in identifying critical prognostic factors, the hope is that they catalyze breakthrough treatments that equably prioritize safety, efficacy, and patient quality of life. The landscape of DLBCL may be daunting, but with diligent research and an unyielding commitment to innovation, the fight against this formidable disease is far from over.

Subject of Research: Prognostic factors of CAR T-cell therapies in diffuse large B-cell lymphoma.

Article Title: Systematic literature review to identify prognostic factors of efficacy and safety outcomes of chimeric antigen receptor T-Cell therapies in diffuse large B-Cell lymphoma.

Article References:

Schleifenbaum, J.K., Heger, JM., Jost, J. et al. Systematic literature review to identify prognostic factors of efficacy and safety outcomes of chimeric antigen receptor T-Cell therapies in diffuse large B-Cell lymphoma. J Cancer Res Clin Oncol 151, 203 (2025). https://doi.org/10.1007/s00432-025-06249-z

Image Credits: AI Generated

DOI: 10.1007/s00432-025-06249-z

Keywords: CAR T-cell therapy, diffuse large B-cell lymphoma, prognostic factors, cytokine release syndrome, personalized medicine, biomarkers, real-world evidence.

The $400,000 Merkin Prize, shared among these four innovators, acknowledges their groundbreaking contributions to biomedical technology that have significantly reshaped cancer treatment paradigms. More than just a breakthrough in oncology, CAR T-cell therapy represents a paradigm shift in precision medicine that harnesses the power of the immune system to fight disease. Patients’ T cells are extracted, genetically engineered in a laboratory environment to express a synthetic receptor targeting cancer-specific proteins, then expanded and infused back into the body. This engineered cellular response equips the immune system to hunt down and destroy tumor cells with formidable specificity and potency.

Richard Merkin, M.D., the prize’s namesake and founder of Heritage Provider Network, emphasizes the profound impact of this technology: “The development of CAR T-cell therapy is a defining moment in biomedical history, an extraordinary example of how foundational scientific insights can be translated into lifesaving therapies. Honoring these scientists underscores the magnitude of their impact on cancer and beyond, positioning us on the cusp of curing millions.”

Administered by the Broad Institute, the Merkin Prize rewards technologies that have meaningfully advanced human health. A rigorous selection process by a committee of distinguished scientific leaders from the academic and industry sectors across the US and Europe vetted this year’s finalists. The winners will be formally recognized in a ceremony later this year, celebrating a milestone in immunotherapy development with significant implications for future medical innovations.

The concept of redirecting the immune system to target cancer thoughtfully harnesses immunological defense mechanisms but faced significant challenges in achieving efficacy and safety. CAR T-cell therapy provides an elegant solution built on genetic engineering principles. By introducing chimeric antigen receptors—synthetic molecules that combine tumor antigen recognition and T-cell activation capabilities—researchers enable T cells to identify and kill cancer cells expressing specific proteins such as CD19, a hallmark of certain blood cancers. These re-engineered T cells demonstrate unparalleled specificity and cytotoxic activity against tumor targets.

Key to this technological leap was Michel Sadelain’s work in the 1990s, then at Memorial Sloan Kettering Cancer Center, where he crafted CARs by fusing antibody fragments with T-cell receptor signaling domains. Sadelain’s innovation laid the molecular groundwork showing that synthetic CAR T cells could provoke a robust immune response upon encountering cancer antigens. His early demonstration of targeting the CD19 protein remains foundational to today’s commercial CAR T-cell therapies.

The challenge of cellular persistence in vivo was addressed by Carl June’s pioneering research at the University of Pennsylvania. In the mid-1990s, June demonstrated that genetically engineered T cells could survive for extended periods within patients, initially studying resistance to HIV infection. This persistence is fundamental, as chronic engagement and elimination of cancer require engineered T cells to remain active within the body for months or years, enabling sustained tumor surveillance and destruction.

Turning these scientific insights into a scalable, clinically viable therapy demanded a remarkable collaborative effort. June and Bruce Levine optimized methods for harvesting, genetically modifying, and expanding patient T cells at therapeutic scale, while Sadelain and Isabelle Rivière refined CAR construct design by incorporating “costimulatory” domains—molecular signals boosting T-cell activation and longevity. This boosting signal enhanced the efficacy and durability of CAR T-cell responses and is now standard in all approved CAR therapies.

From the early 2000s, these teams transitioned their work into clinical applications. The first leukemia patient treatment using personalized CAR T cells occurred in 2007, with Rivière and Sadelain’s team publishing their manufacturing protocols shortly thereafter. Their technology was licensed to Juno Therapeutics, which Bristol Myers Squibb later acquired. Parallel efforts led to FDA approvals in 2017 for CAR T-cell therapies developed by Novartis and Kite Pharmaceuticals, firmly establishing CAR T therapy among frontline treatments for hematological malignancies.

Rivière recalls the “eureka” moment when their first patient treated with CD19-targeted CAR T cells achieved an undetectable leukemia state just weeks post-infusion, a profound testament to the therapy’s curative potential. Similarly, Levine reflected on early trial data showcasing dramatic tumor regression, providing hope to patients facing otherwise fatal relapsed or refractory blood cancers. These clinical successes validated CAR T-cell therapy as a transformative advance in oncology.

Since the first FDA approval, seven CAR T-cell products have emerged addressing multiple blood cancers, including acute lymphoblastic leukemia, large B-cell lymphoma, and multiple myeloma. While these products have been optimized, they all build on the foundational designs and manufacturing strategies developed by June, Levine, Rivière, and Sadelain. The therapy’s demonstrated success has sparked ongoing research into broadening CAR T technology’s applicability beyond oncology.

Clinical trials are now exploring CAR T cells as treatments for autoimmune diseases such as systemic lupus erythematosus, where selective targeting of autoreactive immune cells offers potential to induce remission without global immunosuppression. Additionally, researchers are investigating therapeutic possibilities in infectious diseases, tissue fibrosis, and even age-related degenerative conditions, leveraging the modular nature of CAR designs to target diverse pathological proteins.

Looking forward, advances in CAR engineering—such as next-generation receptors enabling nuanced modulation of T-cell activity—and improvements in cell manufacturing scalability promise to expand access and efficacy. Novel generation CAR T cells aim to overcome current limitations including toxicity, antigen escape, and complex production logistics. As these advances mature, CAR T-cell immunotherapy stands poised to revolutionize precision medicine worldwide, offering hope to millions across a spectrum of life-threatening diseases.

The remarkable journey from molecular design to lifesaving therapy epitomizes the synergy between innovative science, engineering, and clinical translation. The Merkin Prize’s recognition of June, Levine, Rivière, and Sadelain honors not only their scientific brilliance but also their enduring impact on human health—a testament to the remarkable power of harnessing the immune system in the fight against disease.

Subject of Research: Chimeric Antigen Receptor (CAR) T-cell Therapy Development and Clinical Applications

Article Title: Trailblazers Awarded 2025 Merkin Prize for Pioneering CAR T-cell Therapy that Revolutionized Cancer Treatment

News Publication Date: 2025

Web References:
– https://mediasvc.eurekalert.org/Api/v1/Multimedia/9bf29010-73a2-42e7-8151-f17caaf7ac0b/Rendition/low-res/Content/Public
– Broad Institute (https://www.broadinstitute.org)
– University of Pennsylvania Perelman School of Medicine (https://www.med.upenn.edu)
– Memorial Sloan Kettering Cancer Center (https://www.mskcc.org)

Image Credits: University of Pennsylvania Perelman School of Medicine, Columbia University Irving Medical Center

Keywords: CAR T-cell therapy, cancer immunotherapy, chimeric antigen receptor, personalized medicine, leukemia treatment, lymphoma therapy, blood cancers, immuno-oncology, cellular immunotherapy, genetic engineering, precision medicine, biomedical innovation

CAR-T therapy, or chimeric antigen receptor T-cell therapy, revolutionizes cancer treatment by genetically engineering a patient’s own T cells to target and destroy tumor cells with precision. While successes in hematological malignancies have been remarkable, this therapeutic strategy encounters significant obstacles in aged individuals, often the majority demographic of cancer patients. The new research elucidates that CAR-T cells derived from older mice exhibit pronounced mitochondrial dysfunction, reduced stemness characteristics, and severely diminished antitumor potency, presenting a critical barrier to therapy success in the elderly.

At the heart of these impairments lies a decline in the crucial metabolic coenzyme nicotinamide adenine dinucleotide (NAD). NAD plays a pivotal role in cellular energy metabolism, particularly within mitochondria, the cellular organelles responsible for bioenergetics. The study demonstrates that NAD concentrations drop markedly in T cells from older subjects, undermining mitochondrial efficiency and the metabolic fitness required for T cell activation and sustained antitumor responses. This metabolic insufficiency correlates with weakening of the cells’ stem-like properties, which are vital for persistence and long-term efficacy in CAR-T treatments.

Senior and first authors, including Dr. Helen Carrasco Hope and Dr. Nicola Vannini, emphasize that the metabolic deterioration of aged CAR-T cells is not merely a peripheral issue but a fundamental barrier that must be overcome to translate immunotherapy benefits to an aging patient population. Their insights underline how aging intrinsically reshapes immune cell metabolism and function, necessitating that age becomes a central consideration in both preclinical models and clinical trial design. This paradigm shift in designing cancer therapies has profound implications for improving treatment outcomes.

Importantly, the study offers a beacon of hope by demonstrating that the metabolic deficits of aged CAR-T cells are reversible. By employing NAD-boosting compounds—molecules currently undergoing clinical evaluation for other diseases—the researchers successfully restored NAD levels in aged CAR-T cells, reinvigorating their mitochondrial function and replenishing their stem-like qualities. This rejuvenation conferred significant enhancement in the antitumor activity of CAR-T cells derived from aged murine models, marking a pivotal advance toward improving therapeutic efficacy in older patients.

This finding opens up the prospect of combining metabolic reprogramming strategies with conventional CAR-T cell therapy. The approach of NAD restoration not only holds translational potential but also speaks to the broader theme of personalized medicine that accounts for biological age rather than chronological age alone. Metabolic interventions, by targeting cellular bioenergetics, might be used to tailor immunotherapy regimens that adapt to the unique physiological landscapes of elderly cancer patients.

The implications extend beyond CAR-T cells, highlighting a fundamental nuance in aging biology: the immune system is dynamically and detrimentally remodeled at a metabolic level with age. This remodeling compromises various arms of immunity and, by extension, the success of immunotherapies. Establishing age as a biological variable in immuno-oncology research shifts the framework of drug development, clinical trial enrollment, and therapeutic predictive modeling toward a more inclusive and realistic representation of cancer demographics.

This study also sets a precedent for the use of electron microscopy and advanced molecular profiling techniques to dissect immune cell states at high resolution, offering an unprecedented view of the intracellular changes associated with immune senescence. Such detailed cellular insights pave the way for novel biomarkers of immune aging and metabolic fitness that could inform patient stratification and adaptive treatment paradigms.

Furthermore, by targeting NAD metabolism—a pathway implicated in a variety of age-related diseases beyond cancer—this research integrates fields of immunology, oncology, and gerontology, underscoring the multifaceted nature of aging as a biological process. It encourages cross-disciplinary approaches to devise interventions that enhance immune surveillance and resilience in aging populations.

As Dr. Carrasco Hope articulates, these advancements "strengthen the growing recognition that aging fundamentally restructures immune cell function and metabolism," and the research community must heed this call to systematically incorporate age in all stages of immunotherapy development. By doing so, the promise of CAR-T therapy can be extended to a broader, more representative patient base, potentially transforming cancer care for older adults worldwide.

In conclusion, the demonstration that NAD decline underlies CAR-T cell failure in aged organisms—and that this defect can be reversed—marks a transformative moment in immunotherapy research. It challenges existing paradigms, advocates for age-conscious drug development, and opens new therapeutic avenues that could substantially improve the outlook for elderly cancer patients. This study charts a course toward next-generation immunotherapies that are not only effective but also equitable in age-related contexts, marrying cutting-edge science with urgent clinical needs.

Subject of Research: Age-related decline in nicotinamide adenine dinucleotide (NAD) levels compromises CAR-T cell therapy effectiveness.

Article Title: Age-associated nicotinamide adenine dinucleotide decline drives CAR-T cell failure

Web References:
https://doi.org/10.1038/s43018-025-00982-7

Image Credits:
Helen Hope / University of Lausanne (UNIL) (2025)

Keywords: Aging, CAR-T cell therapy, NAD decline, mitochondrial dysfunction, immunotherapy, cancer, T cell metabolism, immune senescence, metabolic rejuvenation